Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 281-289

  Hank, Jacquelyn A ^a,c,e   Surfus, Jean ^c   Gan, Jacek ^c   Albertini, Mark ^c,e   Lindstrom, Mary ^e   Schiller, Joan H ^c,e   Hotton, Kirsten M ^c   Khorsand, Masoud ^b,c   Sondel, Paul M ^c,d,e  

^a Cancer Center ^*  (United States)

^b Cancer Center   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; DRUG INDUCED DISEASE; FEVER; FLOW CYTOMETRY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUSE; NATURAL KILLER CELL; NAUSEA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VOMITING;

ANIMALS; ANTIGENS, CD56; CELL DIVISION; HUMANS; INFUSION PUMPS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTOSIS; MICE; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; REFERENCE STANDARDS; SERUM ALBUMIN; TUMOR CELLS, CULTURED;

EID: 0033011520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., and Rosenberg, S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (Phila.), 58: 2764-2772, 1986.
2. Rosenberg, S. A., Lotze, M. T., and Mule, J. J. NIH conference. New approaches to the immunotherapy of cancer using interluekin-2. Ann. Intern. Med., 108: 853-864, 1988.
3. Kohler, P. C., Hank, J. A., Moore, K. H., Storer, B., Bechhofer, R., and Sondel, P. M. Phase I clinical evaluation of recombinant interleukin-2. In: R. L. Truitt, R. P. Gale, and M. M. Bortin (eds.), Cellular Immunotherapy of Cancer, pp. 161-172. New York: Alan R. Liss, Inc., 1987.
4. Gearing, A. J. H., and Thorpe, R. The international standard for human interleukin-2 calibration by international collaborative study. J. Immunol. Methods, 114: 3-9, 1988.
5. Rossio, J. Cytokines and immune cell products. In: N. Rose, E. deMacario, J. Folds, H. Lane, R. Nakamura, (eds.), Manual of Clinical and Laboratory Immunology, Ed. 5, pp. 348-356. Washington, DC: ASM Press, 1997.
6. Lentsch, A. B., Nakagawa, K., Yoshidome, H., Gerassimides, A., Miller, F. N., and Edwards, M. J. Distinct biological activities of recombinant forms of human interleukin-2 in vivo. Cancer Immunol. Immunother., 43: 331-336, 1997.
7. Schiller, J., Hank, J., Khorsand, M., Storer, B., Borchert, A., Huseby-Moore, K., Burns, D., Wesly, O., Albertini, M., Wilding, G., and Sondel, P. Clinical and immunological effects of granulocyte-macrophage colony stimulating factor co-administered with interleukin-2: a Phase IB study. Clin. Cancer Res., 2: 319-330, 1996.
8. Cause, B. L., Sznol, M., Kopp, W. C., Janik, J. E., Smith, J. W., II, Steis, R. G., Urba, W. J., Sharfman, W., Fenton, R. G., Creekmore, S. P., Holmlund, J., Conlon, K. C., Vandermolen, L. A., and Longo, D. L. Phase I study of subcutaneously administered interleukin-2 in combination with Interferon α-2a in patients with advanced cancer. J. Clin. Oncol., 14: 2234-2241, 1996.
9. Albertini, M. R., Hank, J. A., Schiller, J. H., Khorsand, M., Borchert, A. A., Gan, J., Bechhofer, R., Storer, B., Reisfeld, R. A., and Sondel, P. M. Phase IB trial of chimeric anti-GD2 antibody plus interleukin-2 for melanoma patients. Clin. Cancer Res., 3: 1277-1288, 1997.
10. Rossio, J. L., Thurman, G. B., Long, C., Vargosko, A., and Pinsky, C. The BRMP IL-2 reference reagent. Lymphokine Res., 5, Suppl. 1:S 13-8, 1986.
11. Sondel, P. M., Kohler, P. C., Hank, J. A., Moore, K. H., Rosenthal, N., Sosman. J., Bechhofer, R., and Storer, B. Clinical and immunological effects of recombinant Interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res., 48: 2561-2567, 1988.
12. Farner, N. L., Voss, S. D., Leary, T. P., Gan, J., Hakimi, J., Evans, G., Ju, G., and Sondel, P. M. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood, 86: 4568-4578, 1995.
13. Weil-Hillman, G., Voss, S. D., Fisch, P., Schell, K., Hank, J. A., Sosman, J. A., Sugamura, K., and Sondel, P. M. Natural killer cells activated by interleukin-2 treatment in vivo respond to interleukin-2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res., 50: 2683-2691, 1990.
14. Hank, J. A., Surfus, J. E., Gan, J., Jaeger, P., Gillies, S., Reisfeld, R. A., and Sondel, P. M. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside-GD2/interleukin-2 fusion protein (ch14.18-IL2). Clin. Cancer Res., 2: 1951-1959, 1996.
15. Kohler, P. C., Hank, J. A., Moore, K. H., Storer, B., Bechhofer, R., Hong, R., and Sondel, P. M. Phase I clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion. Cancer Invest., 7: 213-223, 1989.
16. Hank, J. A., Kohler, P. C., Weil-Hillman, G., Rosenthal, N., Moore, K. H., Storer, B., Minkoff, D., Bradshaw, J., Bechhofer, R., and Sondel, P. M. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histo-compatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res., 48: 1965-1971, 1988.
17. Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G. M., Creaven, P. J., Wilkes, K. A., Giedlin, M. A., and Caligiuri, M. A. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin. Cancer Res., 2: 669-677, 1996.
18. Voss, S. D., Hank, J. A., Nobis, C., Fisch, P., Sosman, J. A., and Sondel, P. M. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol. Immunother., 29: 261-269, 1989.
19. Bogner, M. P., Voss, S. D., Bechhofer, R., Hank, J. A., Roper, M., Poplack, D., Hammond, D., and Sondel, P. M. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J. Immunother., 11: 111-118, 1992.
20. Miles, D. W., Bird, C. R., Wadhwa, M., Summerhayes, M., Balkwill, F. R., Thorpe, R., and Rubens, R. D. Reconstitution of interleukin 2 with albumin for infusion. Lancet, 335 (8705): 1602-1603, 1990.
21. Cassidy, J., Poole, C., Sharkie, E., Steward, W. P., and Kaye, S. B. The importance of added albumin during continuous intravenous infu-sion of inter4leukin-2 with α-interferon. Eur. J. Cancer, 27: 1633-1634, 1991.
22. Vlasveld, L. T., Beijnen, J. H., Sein, J. J., Rankin, E. M., Melief, C. C. J., and Hekman, A. Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins. Eur. J. Cancer, 29A: 1977-1979, 1993.
23. Tzammos, S. T., Hrushesky, W. J., Wood, P. A., and Przybycien, T. M. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc. Natl. Acad. Sci. USA, 93: 5460-5465, 1996.
24. Sosman, J. A., Kohler, P. C., Hank, J. A., Moore, K. H., Bechhofer, R., Storer, B., and Sondel, P. M. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J. Natl. Cancer Inst., 80: 60-63, 1988.
25. Schiller, J. H., Hank, J., Storer, B., Borchert, A. A., Huseby-Moore, K., Albertini, M., Bechhofer, R., Wesley, O., Brown, R. R., Mrowca Bastin, A., and Sondel, P. M. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-α in humans. Cancer Res., 53: 1286-1292, 1993.